---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021238"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T13:36:05.205967+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q3 revenue $90.7M, net loss $245.1M ($3.50) on GeneTx charge; reaffirms FY guidance

## Summary
- Total revenue $90.7M (+11% YoY) driven by Crysvita $64.5M (+28% YoY) and Dojolvi $13.3M.
- Net loss $245.1M vs $73.0M in Q3 2021; includes $75.2M R&D expense for GeneTx acquisition.
- Cash & marketable debt securities $996.2M as of Sep 30, includes $491M from OMERS Crysvita royalty sale.
- FY 2022 guidance reaffirmed: Crysvita territories $250-$260M, Dojolvi $55-$65M.

## SEC filing metadata
- accession: 0000950170-22-021238
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017022021238/0000950170-22-021238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017022021238/rare-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021238
- JSON: https://secwatch.observer/filing/0000950170-22-021238.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021238.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported the quarter ended September 30, 2022 results: revenue $90.7 million, net income $245.1 million, EPS $3.50 per share basic and diluted. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2022
  - Revenue: $90.7 million
  - Net income: $245.1 million
  - EPS: $3.50 per share basic and diluted
  - Guidance: reaffirmed
  - Result: reported results
  source text: Third Quarter 2022 Financial Results Net Revenues For the third quarter of 2022, Ultragenyx reported $ 90.7 million in total revenue. Ultragenyx recognized $64.5 million in Crysvita (burosumab) revenue in the Ultragenyx territories, which includes $ 51.3 million in collaboration revenue in the North American profit share territory and net product sales in other regions of $ 13.2 million. Total royalty revenue related to European Crysvita sales was $5.4 million. Dojolvi (triheptanoin) product sales in the third quarter of 2022 were $13.3 million. Mepsevii (vestronidase alfa) product sales for the third quarter of 2022 were $6.0 million. Total revenue for the third quarter of 2022 also includes $1.5 million related to technical assistance following the successful completion of technology transfer activities with Daiichi Sankyo. This compares to total revenue in the third quarter of 2021, which includes $12.1 million related to the technology transfer services which were ongoing at the ti
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017022021238/0000950170-22-021238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.